ClinicalTrials.gg
CompletedNCT02603653MEMOCUSHUpdated Dec 4, 2025

Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease

An interventional study of Virtual radial task in 3D in Cushing's Disease, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Completed at 1 site in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Cushing's disease is a state of chronic endogenous glucocorticoid excess. Cushing's disease is responsible for increased morbidity and mortality. Recent studies have pinpointed the frequency of somatic sequelas and persistent alteration in quality of life despite the cure of the disease. More specifically, a few studies have described persistent psychopathology, maladaptive personality and cognitive impairments in patients with a history of Cushing's disease. Among these, hippocampal memory deficits have been found in the majority of studies, a finding that is consistent with the alterations described in hippocampal neurons during chronic exposure to glucocorticoids. However, the tools currently available to assess hippocampal-dependent memory are multiple, sometimes difficult to perform by clinicians and to analyze or may lack of diagnostic sensitivity. The investigators have recently developed an original tool, the virtual radial task in 3D, which has shown to be reliable to detect subtle alterations in hippocampal-dependent memory in several human diseases. The primary aim of the study is the evaluation of persistent cognitive impairments (hippocampal memory) in patients cured of Cushing's disease for at least one year using the virtual radial task in 3D and to compare it with that obtained with classical cognitive tests.

02

Conditions studied

  • Cushing's Disease
03

In context

Pituitary ACTH Hypersecretion

64 studies on the registry are indexed under Pituitary ACTH Hypersecretion; 16 are open to participants now.

This study's enrollment of 30 is below the median of 44 across 40 interventional studies indexed under Pituitary ACTH Hypersecretion.

Browse Pituitary ACTH Hypersecretion studies →

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients :

  • history of Cushing's Disease
  • aged : 18 - 60 years
  • Biological remission of Cushing's disease for at least one year
  • Affiliation to Social Security
  • signed by patient and investigator (at the latest the inclusion's day, before study's exams)

For controls :

  • People aged 18 to 60 years matched to patients for age, sex and educational level
  • Affiliation to Social Security
  • Informed consent signed by patient and investigator (at the latest the inclusion's day, before study's exams)

Exclusion criteria

Exclusion Criteria:

For patients :

  • Persistent hypercortisolism (even mild)
  • Current treatment of hypercortisolism with drugs
  • Obesity ( >30 kg/m²)
  • Alcohol or drug addiction present or past
  • Growth hormone deficit
  • Diabetes mellitus with > 7.5% and/or fasting blood glucose > 1.4 g/L
  • History of pituitary radiotherapy
  • History of cerebrovascular or neuro-cerebral disease
  • untreated dysthyroidism
  • Current psychotropic drug treatment
  • Pregnancy
  • Use of in the last 3 months before study (aside hydrocortisone replacement therapy)
  • Excessive hydrocortisone replacement therapy (unadjusted to weight and/or with evening administration)

For controls :

  • Obesity (BMI >30 kg/m²)
  • Alcohol or drug addiction present or past
  • Current psychotropic drug treatment
  • History of cerebrovascular or neuro-cerebral disease
  • Current pregnancy
  • Chronical use of corticoid (> 1 month), current or past
  • Use of glucocorticoids in the last 3 months before study (aside hydrocortisone replacement therapy)
  • Diabetes mellitus with hemoglobin A1c > 7.5% and/or fasting blood glucose > 1.4 g/L
  • Obesity (BMI >30 kg/m²)
  • untreated dysthyroidism
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Patients

    Virtual radial task in 3D

    Device: Virtual radial task in 3D

  • Experimental
    Controls

    Virtual radial task in 3D

    Device: Virtual radial task in 3D

Interventions

  • DeviceVirtual radial task in 3D

    The virtual radial task is a labyrinth in 3D with twelve ways. The primary aim of our study is the evaluation of persistent cognitive impairments (hippocampal memory) according to the responses of participants after instructions to choose the right way in the labyrinth.

06

What researchers measure

Primary outcomes

  1. Percentage of right answers at virtual radial task in 3D

    Comparison of right answers in patients cured of Cushing's disease and in controls.

    Time frame: baseline

Secondary outcomes

  1. General Quality of life

    Comparison of quality of life of patients and controls with validated general questionnaire : SF-36 (SF for Short Form health survey)

    Time frame: baseline

  2. Specific Quality of life for Cushing's Disease

    Comparison of quality of life of patients and controls with validated specific questionnaire for Cushing's Disease : Cushing-QoL

    Time frame: baseline

  3. Number of participants with anxiety

    Evaluation of anxiety in the two groups with Hospital Anxiety and Depression Scale (HADS) scale (questionnaire)

    Time frame: baseline

  4. Number of participants with depression with MADRS

    Evaluation of depression in the two groups with Montgomery and Asberg Depression Rating Scale (MADRS) (questionnaire)

    Time frame: baseline

  5. Number of participants with depression with HADS

    Evaluation of depression in the two groups with Hospital Anxiety and Depression Scale (HADS) scale (questionnaire)

    Time frame: baseline

  6. Intensity of Cushing's syndrome

    Intensity of Cushing's disease will be evaluated with mean of free urinary cortisol. Hypothesis : intensity of hypercortisolism is correlated with sequels after cure.

    Time frame: baseline

07

Study locations

1 site
  • Hôpital du Haut-Lévêque
    Pessac, 33604, France
08

References and documents

Publications

  • Pupier E, Santos A, Etchamendy N, Lavielle A, Ferriere A, Marighetto A, Resmini E, Cota D, Webb SM, Tabarin A. Impaired quality of life, but not cognition, is linked to a history of chronic hypercortisolism in patients with Cushing's disease in remission. Front Endocrinol (Lausanne). 2022 Aug 8;13:934347. doi: 10.3389/fendo.2022.934347. eCollection 2022. PubMed 36004342 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02603653
Responsible party
Sponsor
First posted
Nov 13, 2015
Start date
Feb 4, 2016
Primary completion
Feb 12, 2017
Completion
Aug 3, 2017
Last update
Dec 4, 2025

Study contacts

Antoine Tabarin, Pr
principal investigator · Hôpital Haut Lévêque - Pessac (France)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion